FUSION PROTEINS FOR TREATMENT OF CNS

To provide chimeric or fusion proteins capable of systemic use in treatment of spinal cord injuries and related disorders of the central nervous system (CNS).SOLUTION: A fusion peptide comprises a protein transduction domain and a proteoglycan degrading domain. Preferably, the protein transduction d...

Full description

Saved in:
Bibliographic Details
Main Authors GRUSKIN ELLIOTT A, ZIMBER MICHAEL P, ROY GARGI, JENNIFER IACI, CAGGIANO ANTHONY O
Format Patent
LanguageEnglish
Japanese
Published 27.07.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:To provide chimeric or fusion proteins capable of systemic use in treatment of spinal cord injuries and related disorders of the central nervous system (CNS).SOLUTION: A fusion peptide comprises a protein transduction domain and a proteoglycan degrading domain. Preferably, the protein transduction domain is a TAT domain, and a linker polypeptide is present between the protein transduction domain and the proteoglycan degrading domain.SELECTED DRAWING: None 【課題】脊髄損傷及び中枢神経系（ＣＮＳ）の関連疾患の治療における全身的に使用できるキメラ若しくは融合タンパク質の提供。【解決手段】タンパク質形質導入ドメイン、及びプロテオグリカン分解ドメインを有する融合ペプチド、好ましくは、タンパク質形質導入ドメインは、ＴＡＴドメインであり、タンパク質形質導入ドメインおよびプロテオグリカン分解ドメインの間にリンカーポリペプチドを有する、融合ペプチド。【選択図】なし
Bibliography:Application Number: JP20200034479